CLEOCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cleocin, and when can generic versions of Cleocin launch?
Cleocin is a drug marketed by Pharmacia And Upjohn and Pfizer and is included in fourteen NDAs.
The generic ingredient in CLEOCIN is clindamycin palmitate hydrochloride. There are fifty-five drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the clindamycin palmitate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cleocin
A generic version of CLEOCIN was approved as clindamycin palmitate hydrochloride by PADAGIS US on July 7th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLEOCIN?
- What are the global sales for CLEOCIN?
- What is Average Wholesale Price for CLEOCIN?
Summary for CLEOCIN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 14 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 106 |
| Clinical Trials: | 11 |
| Patent Applications: | 4,170 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CLEOCIN |
| Drug Sales Revenues: | Drug sales revenues for CLEOCIN |
| What excipients (inactive ingredients) are in CLEOCIN? | CLEOCIN excipients list |
| DailyMed Link: | CLEOCIN at DailyMed |
Recent Clinical Trials for CLEOCIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Missouri-Columbia | Phase 4 |
| University of California, Los Angeles | Phase 4 |
| National Cancer Institute (NCI) | Phase 4 |
Pharmacology for CLEOCIN
| Drug Class | Lincosamide Antibacterial |
| Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |
US Patents and Regulatory Information for CLEOCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | CLEOCIN | clindamycin hydrochloride | CAPSULE;ORAL | 061809-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CLEOCIN T | clindamycin phosphate | GEL;TOPICAL | 050615-001 | Jan 7, 1987 | AB1 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | CLEOCIN | clindamycin phosphate | SUPPOSITORY;VAGINAL | 050767-001 | Aug 13, 1999 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CLEOCIN | clindamycin phosphate | CREAM;VAGINAL | 050680-002 | Mar 2, 1998 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | CLEOCIN PHOSPHATE | clindamycin phosphate | INJECTABLE;INJECTION | 062803-001 | Oct 16, 1987 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CLEOCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | CLEOCIN | clindamycin phosphate | SUPPOSITORY;VAGINAL | 050767-001 | Aug 13, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CLEOCIN
See the table below for patents covering CLEOCIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 250408 | ⤷ Sign Up | |
| European Patent Office | 1200065 | COMPOSITION D'OVULE CLINDAMYCINE INTRAVAGINALE (INTRAVAGINAL CLINDAMYCIN OVULE COMPOSITION) | ⤷ Sign Up |
| Mexico | PA02001320 | COMPOSICION INTRAVAGINAL DE CLINDAMICINA EN FORMA DE OVULO. (INTRAVAGINAL CLINDAMYCIN OVULE COMPOSITION.) | ⤷ Sign Up |
| China | 1360495 | ⤷ Sign Up | |
| Canada | 2378572 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CLEOCIN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1304992 | 92401 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
| 1304992 | 122013000081 | Germany | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322 |
| 1304992 | 2013/044 | Ireland | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322 |
| 1304992 | C01304992/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014 |
| 1304992 | C300617 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
